PET scan imaging in oncology.

[1]  R. Hustinx,et al.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  F. Howe,et al.  Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. , 2002, European journal of cancer.

[3]  J G Fletcher,et al.  CT colonography (virtual colonoscopy) for the detection of colorectal polyps and neoplasms. current status and future developments. , 2002, European journal of cancer.

[4]  A R Padhani,et al.  Functional MRI for anticancer therapy assessment. , 2002, European journal of cancer.

[5]  K. Miles,et al.  Functional computed tomography in oncology. , 2002, European journal of cancer.

[6]  R. Blasberg.  PET imaging of gene expression. , 2002, European journal of cancer.

[7]  R. Eckersley,et al.  Functional ultrasound methods in oncological imaging. , 2002, European journal of cancer.

[8]  A. Peters,et al.  Gamma camera imaging in malignancy. , 2002, European journal of cancer.

[9]  P. Price,et al.  PET for in vivo pharmacokinetic and pharmacodynamic measurements. , 2002, European journal of cancer.

[10]  M. Sculpher,et al.  Assessment of the technology for functional imaging in cancer. , 2002, European journal of cancer.

[11]  Johan Nuyts,et al.  Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  I. Carrió,et al.  FDG-PET improves the management of patients with suspected recurrence of colorectal cancer , 2002, Nuclear medicine communications.

[13]  R. Hustinx,et al.  The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Ying Lu,et al.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. , 2002, Radiology.

[15]  C. Claussen,et al.  Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma , 2002, Cancer.

[16]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[17]  W. Oyen,et al.  Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Diehl,et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.

[19]  D. Rades,et al.  Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  F. Chierichetti,et al.  Value of 18-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients With Cystic Tumors of the Pancreas , 2001, Annals of surgery.

[21]  A. Garden,et al.  Can positron emission tomography improve the quality of care for head-and-neck cancer patients? , 2001, International journal of radiation oncology, biology, physics.

[22]  B. Weynand,et al.  PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[23]  C. Bokemeyer,et al.  Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Price,et al.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer. , 2001, Thorax.

[25]  R. Hustinx,et al.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. O'Doherty,et al.  Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  O. Hoekstra,et al.  Systematic review of the diagnostic accuracy of 18F‐fluorodeoxyglucose positron emission tomography in melanoma patients , 2001 .

[28]  B. Siegel,et al.  Survival of Patients Evaluated by FDG-PET Before Hepatic Resection for Metastatic Colorectal Carcinoma: A Prospective Database Study , 2001, Annals of surgery.

[29]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[30]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Buchert,et al.  18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  S. Yasuda,et al.  Application of positron emission tomography imaging to cancer screening , 2000, British Journal of Cancer.

[33]  D. Tyler,et al.  Positron emission tomography scanning in malignant melanoma , 2000 .

[34]  M. Remacle,et al.  Positron Emission Tomography With Fluorodeoxyglucose for Suspected Head and Neck Tumor Recurrence in the Symptomatic Patient , 2000, The Laryngoscope.

[35]  M. Schwaiger,et al.  Preoperative Evaluation of Pancreatic Masses with Positron Emission Tomography Using 18F-fluorodeoxyglucose: Diagnostic Limitations , 2000, World Journal of Surgery.

[36]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[37]  S S Gambhir,et al.  A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  G. Jerusalem,et al.  Commentary on “Positron Emission Tomography in Lymphoma: Comparison with Computed Tomography and Gallium-67 Single Photon Emission Computed Tomography Imaging” , 2000 .

[39]  L. Kostakoglu,et al.  Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography. , 2000, Clinical lymphoma.

[40]  J A Werner,et al.  FDG PET detection of unknown primary tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  R. Hustinx,et al.  Evaluation thérapeutique précoce par tomographie à émission de positons , 2000 .

[42]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[43]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[44]  R L Wahl,et al.  Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. , 1999, Radiology.

[45]  L. Einhorn,et al.  Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  F. Gherlinzoni,et al.  The role of positron emission tomography (PET) in the management of lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[49]  L. Friberg,et al.  18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). , 1999, European Journal of Cancer.

[50]  K. Greven,et al.  Occult primary tumors of the head and neck , 1999, Cancer.

[51]  J. J. Coleman,et al.  Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Singer,et al.  Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. , 1999, Radiology.

[53]  R. Coleman,et al.  The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma , 1998, Cancer.

[54]  P. Valk,et al.  Analytical decision model for the cost-effective management of solitary pulmonary nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Roodenburg,et al.  Detection of unknown occult primary tumors using positron emission tomography , 1998, Cancer.

[56]  B. Siegel,et al.  Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. , 1998, Annals of surgery.

[57]  I. Fogelman,et al.  Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. , 1996, Seminars in nuclear medicine.

[58]  M Schwaiger,et al.  Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. , 1996, Journal of the National Cancer Institute.

[59]  S S Gambhir,et al.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[61]  F. Shishido,et al.  Clinical Value of Pet with 18F-Fluorodeoxyglucose and L-Methyl-11C-Methionine for Diagnosis of Recurrent Brain Tumor and Radiation Injury , 1991, Acta radiologica.

[62]  A. Wolf,et al.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.